Share:

E-Eye uses patented IRPL® (Intense Regulated Pulsed Light) technology specifically designed for the treatment of Dry Eye due to Meibomian Gland Dysfunction (MGD).

E-Eye’s IRPL® technology helps to regenerate the function of the Meibomian glands and improve the quality of their secretions. This new type of polychromatic pulsed light produces perfected calibrated and homogenously sequenced light pulses which stimulate the parasympathetic nerves. This in turn encourages the Meibomian glands to restore their natural lipid flow, reducing tear evaporation and preventing the eyes from becoming dry.

In most cases, Dry Eye symptoms will significantly improve after 3 sessions, carried out over 45 days. For 60% of patients results can last up to 3 years.

• Painless, non-invasive and affordable
• Fast results – sessions are completed in a matter of minutes
• Clinical studies with a 90% satisfaction rate on the first 2 sessions
• 95.7% of patients recommend the treatment
• 55% of patients don’t use eye drops anymore
• 82.6% of patients have symptom improvements

Brian Bowles, Managing Director of Grafton Optical says “We have seen huge interest and success with the E-Eye since its launch in the UK last year. It offers huge benefits not only to patients suffering from MGD related Dry Eye but also to practices wishing to increase their income.”

How E-Eye will have a positive impact on practices

Meibomian Gland Dysfunction (MGD) is one of the most common causes of dry eye, resulting in a range of symptoms which include dryness, burning, foreign body sensation and blurred vision.

IRPL® therapy offers a newly advanced choice for MGD patients to achieve significantly longer term relief from what is becoming an ever more prevalent and in some cases, very debilitating condition. Multiple clinical studies have demonstrated that the E-Eye is able to rapidly relieve the symptoms and signs of MGD both safely and effectively.

E-Eye also offers patients a way to manage their symptoms that doesn’t rely on patient compliance in the same way that alternative treatments do. Unlike eye drops, for example, the E-Eye requires a series of three treatments, after which symptoms can remain dramatically decreased without further action by the patient, in some cases, for up to three years.

What differentiates E-Eye to other alternatives in the market?

E-Eye is the only dry eye specific IRPL® device on the market that has been clinically validated for the management of dry eye syndrome. The IRPL® technology behind the device has been specifically designed to target the Meibomian glands and parasympathetic nerves.

E-Eye generates a polychromatic-pulsed light, producing perfectly calibrated and homogenously sequenced light pulses. These sculpted pulses are delivered under the shape of pulse trains, the energy, spectrum and duration of which are precisely set to stimulate and unblock the Meibomian glands, in order to regenerate their function.

The benefits of the E-Eye therapy are multiple; both improving comfort for contact lens wearers and reducing or eliminating symptoms for dry eye sufferers. Many other products on the market are aimed at substituting the lipid layer of the eye, while E-Eye works to stimulate the eye’s own ability to do this naturally.

E-Eye has been fully developed and manufactured in France by E-Swin, the world’s largest IPL device manufacturer. Grafton Optical introduced E-Eye into the UK market in late 2016. 

E-Eye rental scheme

As well as being available for purchase, Grafton Optical have now introduced an E-Eye rental scheme throughout the UK and Ireland.

• The rental scheme will be available on a 6-month term, after which customers can opt to purchase the device at a reduced cost to take into account rental payments
• A full marketing support package will be available to all rental and purchase customers to assist with successful implementation
• The rental scheme will make E-Eye accessible to more practices without the initial high investment costs. This will allow practitioners to realise the demand for the device amongst their Dry Eye patients, and the financial impact that this can have on their practice in terms of increased revenue

For more details on pricing and marketing support, please contact Grafton Optical on 01923 233980 or [email protected]

“The E-Eye has proved to be a wonderful instrument - giving us the opportunity and freedom to treat dry eyes rather than just recommending eye drops.

Patients have found the therapy to be simple and effective. They cannot believe how a flash of light can make the tears flow smoothly.

E-Eye has provided an extra armoury in our general practice to treat the scourge of dry eyes which can make life a misery for patients, giving them soreness, blurred vision and red eyes.”

Kirit Patel, MBCO Bsc (Hons) - Radlett Opticians